Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China · Delayed Price · Currency is CNY 15.11
+0.13 (0.87%)
Apr 28, 2026, 3:00 PM CST
SHA:600535 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 1,161 | 1,105 | 955.59 | 1,071 | -264.24 | 2,359 |
Depreciation & Amortization | 447.57 | 447.57 | 496.2 | 504.91 | 517.95 | 487.77 |
Other Amortization | 17.04 | 17.04 | 6.3 | 11.23 | 14.73 | 15.23 |
Loss (Gain) From Sale of Assets | -8.61 | -8.61 | -2.11 | -0.15 | -1.48 | -44.22 |
Asset Writedown & Restructuring Costs | 56.95 | 56.95 | 218.01 | 1.78 | 352.26 | 265.48 |
Loss (Gain) From Sale of Investments | 16.74 | 16.74 | 198.5 | 270.75 | 1,158 | -1,682 |
Provision & Write-off of Bad Debts | 20.88 | 20.88 | -0.23 | 8.19 | -1.34 | -5.35 |
Other Operating Activities | 715.91 | -55.15 | -72.94 | -2.03 | -31.24 | 123.82 |
Change in Accounts Receivable | -522.68 | -522.68 | 78.22 | 1,243 | 535.51 | 1,231 |
Change in Inventory | 268.46 | 268.46 | 18.32 | -220.72 | -2.86 | -198.37 |
Change in Accounts Payable | 66.85 | 66.85 | 121.58 | -395.35 | 36.56 | 243.78 |
Change in Other Net Operating Assets | - | - | - | 67.76 | 11.01 | 3.44 |
Operating Cash Flow | 2,252 | 1,425 | 2,015 | 2,576 | 2,280 | 2,801 |
Operating Cash Flow Growth | 13.20% | -29.28% | -21.78% | 12.98% | -18.62% | 56.39% |
Capital Expenditures | -273.45 | -381.26 | -564.94 | -668.82 | -404.41 | -571.73 |
Sale of Property, Plant & Equipment | 1.37 | 6 | 27.58 | 1.19 | 1.34 | 68.92 |
Cash Acquisitions | - | - | - | - | - | -147.31 |
Divestitures | - | 83.38 | - | - | - | 424.19 |
Investment in Securities | -1,175 | -209.9 | -382.07 | -134.14 | -919.91 | 126.42 |
Other Investing Activities | 52.44 | 55.3 | -21.49 | -1,307 | 56.75 | 56.76 |
Investing Cash Flow | -1,395 | -446.48 | -940.87 | -2,109 | -1,266 | -42.83 |
Short-Term Debt Issued | - | 970 | 1,052 | 213.91 | 102.79 | 1 |
Long-Term Debt Issued | - | 884.39 | 1,451 | 1,817 | 2,711 | 1,441 |
Total Debt Issued | 1,693 | 1,854 | 2,504 | 2,031 | 2,814 | 1,442 |
Short-Term Debt Repaid | - | -500 | -1,132 | -127 | -9.87 | -82.14 |
Long-Term Debt Repaid | - | -1,585 | -2,597 | -1,345 | -2,311 | -2,717 |
Total Debt Repaid | -1,832 | -2,085 | -3,729 | -1,472 | -2,321 | -2,799 |
Net Debt Issued (Repaid) | -139.15 | -230.79 | -1,225 | 559.55 | 492.71 | -1,358 |
Repurchase of Common Stock | - | - | - | - | -60.8 | -56.43 |
Common Dividends Paid | -327.31 | -632.7 | -1,042 | -563.22 | -553.97 | -610.49 |
Other Financing Activities | -510.84 | 493.38 | -186.05 | -1,193 | -114.58 | -458.73 |
Financing Cash Flow | -977.3 | -370.11 | -2,454 | -1,196 | -236.63 | -2,483 |
Foreign Exchange Rate Adjustments | -20.16 | -10.36 | 0.16 | -1.26 | 30.39 | 1.94 |
Net Cash Flow | -140.57 | 597.8 | -1,380 | -730.54 | 807.36 | 276.97 |
Free Cash Flow | 1,978 | 1,043 | 1,450 | 1,907 | 1,875 | 2,229 |
Free Cash Flow Growth | 45.27% | -28.02% | -23.98% | 1.68% | -15.89% | 61.28% |
Free Cash Flow Margin | 23.70% | 12.67% | 17.06% | 21.98% | 21.71% | 28.04% |
Free Cash Flow Per Share | 1.32 | 0.70 | 0.97 | 1.28 | 1.28 | 1.48 |
Cash Interest Paid | 5.51 | 5.51 | 8.41 | - | 4.05 | - |
Cash Income Tax Paid | 1,035 | 1,062 | 993.38 | 1,099 | 1,106 | 1,008 |
Levered Free Cash Flow | -616.41 | 840.85 | 968.19 | 1,348 | 1,517 | 2,531 |
Unlevered Free Cash Flow | -596.1 | 861.16 | 1,006 | 1,400 | 1,557 | 2,580 |
Change in Working Capital | -175.63 | -175.63 | 215.24 | 709.88 | 535.21 | 1,281 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.